Journal
BRAIN SCIENCES
Volume 9, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/brainsci9010017
Keywords
Fragile X syndrome 1; Fragile X-associated Tremor/Ataxia Syndrome 2; CRISPR 3; Trinucleotide Repeat 4; Gene editing
Categories
Funding
- Burroughs Wellcome Fund Postdoctoral Enrichment Program
- University of Pennsylvania Academic Diversity Fellowship
- Children's Hospital of Philadelphia Research Institute
Ask authors/readers for more resources
Gene-editing using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is promising as a potential therapeutic strategy for many genetic disorders. CRISPR-based therapies are already being assessed in clinical trials, and evaluation of this technology in Fragile X syndrome has been performed by a number of groups. The findings from these studies and the advancement of CRISPR-based technologies are insightful as the field continues towards treatments and cures of Fragile X-Associated Disorders (FXADs). In this review, we summarize reports using CRISPR-editing strategies to target Fragile X syndrome (FXS) molecular dysregulation, and highlight how differences in FXS and Fragile X-associated Tremor/Ataxia Syndrome (FXTAS) might alter treatment strategies for each syndrome. We discuss the various modifications and evolutions of the CRISPR toolkit that expand its therapeutic potential, and other considerations for moving these strategies from bench to bedside. The rapidly growing field of CRISPR therapeutics is providing a myriad of approaches to target a gene, pathway, or transcript for modification. As cures for FXADs have remained elusive, CRISPR opens new avenues to pursue.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available